C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.
CEO: |
Clive Dix |
CFO: |
Bradley Hoy |
Non-Executive Director: |
Alexander James Stevenson, Simon Harford, Natalie Walter |
Non-Executive Chairman: |
Eva-Lotta Allan |
Chief Business Officer: |
Bhavna Hunjan |
Address: |
Manchester One, 53 Portland Street, Manchester, United Kingdom |
Phone: |
+44 (0)161 235 5085 |
Fax: |
|
Website: |
http://www.c4xdiscovery.com |
Email: |
|